Onesource Specialty Pharma Limited (ONESOURCE) — Announcement | 14 July 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
OneSource partners with Formycon for biosimilars manufacturing
💡 Investor Takeaway
This partnership strengthens OneSource's position as a key CDMO in global biosimilar supply chains.

OneSource Specialty Pharma announced a strategic manufacturing partnership with Formycon AG to co-develop and manufacture biosimilars using its Bangalore facility, leveraging Formycon's development expertise and OneSource's integrated biologics manufacturing capabilities to expand global access to affordable biosimilars.

📄 View Original Announcement (PDF)

About Onesource Specialty Pharma Limited (ONESOURCE)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹17,366.55 Cr ROE: -0.8% ROCE: 0.9%

View full ONESOURCE stock details →

📡 Get AI alerts when ONESOURCE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ONESOURCE — Free

📊 More ONESOURCE filings

See all ONESOURCE filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ONESOURCE files new disclosures

Track ONESOURCE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ONESOURCE — Free

Free account · 2 AI queries/day